New findings from the Phase II MiSLE trial, funded by the Lupus Foundation of America (LFA), have identified encouraging disease-improvement signals with umbilical cord-derived mesenchymal stromal cells (MSCs) in adults with active systemic lupus erythematosus (SLE) who had an inadequate response to standard treatment.
Presented as a late-breaking abstract at the American College of Rheumatology (ACR) Annual Meeting on November 10, 2026, the study evaluated a single intravenous infusion of MSCs at two dose levels.
Although the trial did not meet its primary efficacy endpoint at Week 24 when both MSC dose groups were combined and compared with placebo, secondary analyses showed greater improvements among patients receiving the higher dose. The findings are expected to guide the design of a confirmatory clinical trial.
Phase II MiSLE Trial: Study Design
The MiSLE study is the first multicentre, randomized, double-blind, placebo-controlled trial evaluating allogeneic umbilical cord-derived MSCs in adults with active SLE.
Conducted across nine US lupus centres, the study enrolled 87 randomized participants, of whom 81 received an infusion:
-
Low-dose MSC group: 27 patients received 1 million cells/kg.
-
High-dose MSC group: 27 patients received 5 million cells/kg.
-
Placebo group: 27 patients received placebo.
The primary efficacy analysis included 80 participants after one placebo recipient withdrew consent.
The primary endpoint was the proportion of patients achieving a response at Week 24 based on a modified Systemic Lupus Erythematosus Responder Index-4 (SRI-4). The measure assessed improvements in disease activity while limiting worsening disease and increases in medication use, including a prednisone dose of no more than 10 mg daily from Week 20.
Primary Endpoint Not Met
At Week 24, 38.9% of participants receiving MSCs achieved the modified SRI-4 response criteria, compared with 23.1% in the placebo group.
This represented a 15.8-percentage-point difference favouring MSC treatment. However, the result did not reach statistical significance (adjusted p = 0.156).
Despite missing the primary endpoint, additional analyses identified stronger response signals in the high-dose group.
Key Secondary Findings
1. Higher-dose response at Week 24
The response rate was:
-
High-dose MSC group: 48.1%.
-
Low-dose MSC group: 29.6%.
-
Pooled placebo group: 23.1%.
The high-dose group showed a 25-percentage-point improvement over placebo, approaching statistical significance (adjusted p = 0.054).
2. Earlier response signals
Secondary analyses using the unmodified SRI-4 showed statistically significant benefits for the higher-dose group compared with its within-cohort placebo group at Weeks 12, 16 and 20 (p = 0.03–0.04 at each time point).
3. Per-protocol analysis
Among participants without major protocol deviations before Week 24, the response rate was:
-
High-dose MSC group: 68.4% (13 of 19).
-
Pooled placebo group: 30.0% (6 of 20).
This difference was statistically significant (adjusted p = 0.0087). However, this analysis involved a smaller subset of participants and should be interpreted separately from the primary intention-to-treat analysis.
4. Disease activity over time
Disease activity, measured using the SLE Disease Activity Index (SLEDAI), declined across all three groups.
At Week 12, median SLEDAI scores decreased by four points in both MSC groups, compared with two points in the placebo group. At Week 24, the high-dose group showed a greater median reduction than the other two groups.
By Week 52, the low-dose group had the largest median decrease of six points. However, differences in baseline disease activity limited direct comparisons between treatment groups. Additionally, after Week 24, participants could receive other immunosuppressants, biologics or prednisone, complicating the interpretation of longer-term results.
Safety Profile Through Week 52
Safety was evaluated through Week 52. Serious adverse events (SAEs) occurred in 27.8% of MSC-treated participants, compared with 14.8% of placebo recipients.
The reported SAE rates were:
-
Low-dose MSC group: 44.4%.
-
High-dose MSC group: 11.1%.
-
Placebo group: 14.8%.
None of the serious adverse events was attributed to the study treatment.
Serious infections occurred in 7.4% of MSC-treated participants, compared with 3.7% of placebo recipients. The high-dose MSC group had fewer reported infections than the low-dose group.
One death by suicide occurred in the placebo group early in the study. No deaths were reported among the 54 participants who received MSC treatment.
The investigators described the overall safety findings as reassuring, although the differences in adverse-event rates between the small treatment groups warrant further evaluation.
Next Step: Confirmatory Trial Planned
Based on the higher-dose response signals, the research team is developing a confirmatory study focused on the 5 million cells/kg dose.
The planned trial is expected to further evaluate the potential of MSC therapy, including repeat dosing to determine whether early improvements can be sustained over time.
The findings were presented by Diane L. Kamen, MD, MSCR, Professor in the Division of Rheumatology and Immunology at the Medical University of South Carolina (MUSC). The study was authored by Gary S. Gilkeson, MD, Distinguished University Professor at MUSC.
About Mesenchymal Stromal Cell Therapy in Lupus
Umbilical cord-derived MSCs are donor-derived cells being investigated for their ability to regulate immune activity. In autoimmune conditions such as SLE, the immune system mistakenly attacks the body's own tissues and organs.
The MiSLE trial explored whether a single infusion of these cells could improve disease activity in patients whose lupus remained active despite standard treatment.
The Lupus Foundation of America has supported MSC research since 2012, including a $3.8 million funding commitment announced in 2018 for the Phase II trial. The study was supported by the foundation and the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH).
Conclusion
The MiSLE Phase II results provide encouraging signals for higher-dose umbilical cord-derived MSC therapy in adults with active systemic lupus erythematosus. However, the study did not meet its primary endpoint, and the positive findings came from secondary and per-protocol analyses.
The planned confirmatory trial will be important in determining whether the higher dose can deliver reproducible and sustained clinical benefits and establish the therapy's role in lupus treatment.